News
ATHE
5.07
+2.12%
0.11
Weekly Report: what happened at ATHE last week (0615-0619)?
Weekly Report · 3d ago
Alterity Therapeutics Files June 2026 Form 6-K Highlighting Changes in Directors’ Interests
TipRanks · 06/17 10:29
Alterity Therapeutics Price Target Announced at $10.00/Share by Ladenburg Thalmann
Dow Jones · 06/16 17:04
Alterity Therapeutics Coverage Assumed by Ladenburg Thalmann at Buy
Dow Jones · 06/16 17:04
Alterity Therapeutics assumed with a Buy at Ladenburg
TipRanks · 06/16 11:57
Alterity Therapeutics Files June 2026 Corporate Presentation With U.S. Regulator
TipRanks · 06/16 10:28
Alterity Therapeutics Files Form 6-K on Unquoted Securities Notification
TipRanks · 06/15 10:33
Alterity Therapeutics Files June Form 6-K Highlighting Cessation of Certain Securities
TipRanks · 06/15 10:32
Weekly Report: what happened at ATHE last week (0608-0612)?
Weekly Report · 06/15 09:05
Alterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval
TipRanks · 06/12 10:28
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Alterity Therapeutics (ATHE)
TipRanks · 06/10 18:20
Alterity Aligns With FDA On Phase 3 Design For ATH434 In Treating Multiple System Atrophy
NASDAQ · 06/10 09:07
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder
Benzinga · 06/09 15:41
Alterity, FDA agree on phase 3 program for multiple system atrophy asset ATH434
Seeking Alpha · 06/09 11:34
Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA
TipRanks · 06/09 11:21
At a glance: stocks gapping up premarket
Seeking Alpha · 06/09 11:17
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
TipRanks · 06/09 10:29
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
Barchart · 06/09 06:05
Weekly Report: what happened at ATHE last week (0601-0605)?
Weekly Report · 06/08 09:05
Alterity Therapeutics management to meet with BTIG
TipRanks · 06/03 17:30
More
Webull provides a variety of real-time ATHE stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ATHE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.